In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts
Pancreatic cancer is one of the leading cancer-related causes of death in the western world with an urgent need for new treatment strategies. Recently, hyperforin and nemorosone have been described as promising anti-cancer lead compounds. While hyperforin has been thoroughly investigated in vitro an...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 5, 2013
|
| In: |
PLOS ONE
Year: 2013, Jahrgang: 8, Heft: 9, Pages: 1-8 |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0074555 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1371/journal.pone.0074555 Verlag, lizenzpflichtig, Volltext: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0074555 
|
| Verfasserangaben: | Robert J. Wolf, Ralf A. Hilger, Jörg D. Hoheisel, Jens Werner, Frank Holtrup |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1764145070 | ||
| 003 | DE-627 | ||
| 005 | 20230426140739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210722s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0074555 |2 doi | |
| 035 | |a (DE-627)1764145070 | ||
| 035 | |a (DE-599)KXP1764145070 | ||
| 035 | |a (OCoLC)1341419805 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wolf, Robert |d 1986- |e VerfasserIn |0 (DE-588)1047083027 |0 (DE-627)77753732X |0 (DE-576)400378205 |4 aut | |
| 245 | 1 | 0 | |a In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts |c Robert J. Wolf, Ralf A. Hilger, Jörg D. Hoheisel, Jens Werner, Frank Holtrup |
| 264 | 1 | |c September 5, 2013 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.07.2021 | ||
| 520 | |a Pancreatic cancer is one of the leading cancer-related causes of death in the western world with an urgent need for new treatment strategies. Recently, hyperforin and nemorosone have been described as promising anti-cancer lead compounds. While hyperforin has been thoroughly investigated in vitro and in vivo, in vivo data for nemorosone are still missing. Thus, we investigated the growth-inhibitory potential of nemorosone on pancreatic cancer xenografts in NMRI nu/nu mice and determined basic pharmacokinetic parameters. Xenograft tumors were treated with nemorosone and gemcitabine, the current standard of care. Tumor sections were subjected to H&E as well as caspase 3 and Ki-67 staining. Nemorosone plasma kinetics were determined by HPLC and mass spectrometry. Induction of CYP3A4 and other metabolizing enzymes by nemorosone and hyperforin was tested on primary hepatocytes using qRT-PCR. At a dose of 50 mg/kg nemorosone per day, a significant growth-inhibitory effect was observed in pancreatic cancer xenografts. The compound was well tolerated and rapidly absorbed into the bloodstream with a half-life of approximately 30 min. Different metabolites were detected, possibly resembling CYP3A4-independent oxidation products. It is concluded that nemorosone is a potential anti-cancer lead compound with good bioavailability, little side-effects and promising growth-inhibitory effects, thus representing a valuable compound for a combination therapy approach. | ||
| 650 | 4 | |a Blood plasma | |
| 650 | 4 | |a Cancer treatment | |
| 650 | 4 | |a Cancers and neoplasms | |
| 650 | 4 | |a Drug metabolism | |
| 650 | 4 | |a Enzyme metabolism | |
| 650 | 4 | |a Hepatocytes | |
| 650 | 4 | |a Metabolites | |
| 650 | 4 | |a Pancreatic cancer | |
| 700 | 1 | |a Hoheisel, Jörg D. |d 1958- |e VerfasserIn |0 (DE-588)1128674645 |0 (DE-627)883097397 |0 (DE-576)486011305 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PLOS ONE |d San Francisco, California, US : PLOS, 2006 |g 8(2013), 9, Artikel-ID e74555, Seite 1-8 |h Online-Ressource |w (DE-627)523574592 |w (DE-600)2267670-3 |w (DE-576)281331979 |x 1932-6203 |7 nnas |a In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts |
| 773 | 1 | 8 | |g volume:8 |g year:2013 |g number:9 |g elocationid:e74555 |g pages:1-8 |g extent:8 |a In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts |
| 856 | 4 | 0 | |u https://doi.org/10.1371/journal.pone.0074555 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0074555 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210722 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 1128674645 |a Hoheisel, Jörg D. |m 1128674645:Hoheisel, Jörg D. |d 50000 |e 50000PH1128674645 |k 0/50000/ |p 3 | ||
| 998 | |g 1047083027 |a Wolf, Robert |m 1047083027:Wolf, Robert |d 910000 |d 911400 |e 910000PW1047083027 |e 911400PW1047083027 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1764145070 |e 3956878124 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"title":[{"title":"PLOS ONE","title_sort":"PLOS ONE"}],"part":{"year":"2013","pages":"1-8","issue":"9","volume":"8","text":"8(2013), 9, Artikel-ID e74555, Seite 1-8","extent":"8"},"pubHistory":["1.2006 -"],"recId":"523574592","language":["eng"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"Public Library of Science"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenograftsPLOS ONE","note":["Schreibweise des Titels bis 2012: PLoS ONE","Gesehen am 20.03.19"],"id":{"issn":["1932-6203"],"eki":["523574592"],"zdb":["2267670-3"]},"origin":[{"publisherPlace":"San Francisco, California, US ; Lawrence, Kan.","dateIssuedKey":"2006","publisher":"PLOS ; PLoS","dateIssuedDisp":"2006-"}],"name":{"displayForm":["Public Library of Science"]},"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Robert J. Wolf, Ralf A. Hilger, Jörg D. Hoheisel, Jens Werner, Frank Holtrup"]},"id":{"eki":["1764145070"],"doi":["10.1371/journal.pone.0074555"]},"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"September 5, 2013"}],"language":["eng"],"recId":"1764145070","note":["Gesehen am 22.07.2021"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"given":"Robert","family":"Wolf","role":"aut","display":"Wolf, Robert","roleDisplay":"VerfasserIn"},{"family":"Hoheisel","given":"Jörg D.","roleDisplay":"VerfasserIn","display":"Hoheisel, Jörg D.","role":"aut"}],"title":[{"title_sort":"In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts","title":"In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts"}]} | ||
| SRT | |a WOLFROBERTINVIVOACTI5201 | ||